Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Sierra Oncology
Sierra Oncology
GSK explores new avenues for JAK drug in $1.9B Sierra buy amid pending FDA decision
Fierce Biotech
Mon, 12/12/22 - 10:23 am
GSK
Sierra Oncology
momelotinib
myelofibrosis
ASH 2022
Shortly after selling Sierra to GSK, Stephen Dilly heads to enzyme engineer Codexis as new CEO
Endpoints
Tue, 07/19/22 - 10:24 am
Sierra Oncology
Stephen Dilly
GSK
Codexis
Biopharma takeout spend ticks up
EP Vantage
Tue, 07/5/22 - 11:02 am
M&A
biotech
Pfizer
Biohaven
Bristol Myers Squibb
Turning Point Therapeutics
GSK
Affinivax
Sierra Oncology
Halozyme Therapeutics
Antares Pharma
Was This Acquisition a Smart Move for GlaxoSmithKline?
Motley Fool
Sun, 05/15/22 - 11:10 pm
GSK
Sierra Oncology
momelotinib
bone marrow cancer
M&A
GSK to buy Sierra Oncology amid pressure to boost drug pipeline
Reuters
Wed, 04/13/22 - 05:39 pm
GSK
Sierra Oncology
M&A
Sierra Oncology records success in late-stage study of bone cancer drug
BioPharma Dive
Tue, 01/25/22 - 10:47 am
Sierra Oncology
bone cancer
clinical trials
With an assist from AstraZeneca, the salvage crew at Sierra bets another $216M they can resurrect an old Gilead JAK drug
Endpoints
Fri, 08/6/21 - 11:07 am
Gilead Sciences
AstraZeneca
Sierra Oncology
AZD5153
oncology
Sierra doubles down on ex-Gilead drug, deprioritizes other assets
Fierce Biotech
Fri, 06/28/19 - 12:28 pm
Sierra Oncology
myelofibrosis
Gilead Sciences
momelotinib